Harrow, Inc. · NASDAQ:HROW

Harrow — Q3 2026 Earnings Presentation

30 slides from Harrow's earnings presentation, Nov 10, 2026

  1. Slide 1: Corporate Presentation November 2026

    Corporate Presentation November 2026

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation contains “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptio

  3. Slide 3: Harrow. We Are Ophthalmic Pharma.

    Harrow. We Are Ophthalmic Pharma. Diversified provider of ophthalmic disease management solutions in North America Largest U.S. Portfolio of Prescription Multiple Growth Drivers Across Large Scalable Commercial Platform Ophthalmic Products Ophthalmic Markets PORTFOLIO BREADTH SELECT PRODUCTS KEY DIF

  4. Slide 4: Investment Highlights

    Investment Highlights Multiple growth drivers, a scalable commercial platform, and a new product every year Q3 YOY DEMAND GROWTH Early-Stage Growth, Durable Franchises KEY DRIVERS +83% +21% +110% 1 Major growth drivers remain early in their adoption curves, VEVYE · IHEEZO addressing large markets wi

  5. Slide 5: Durable Growth: A New Product Every Year

    Durable Growth: A New Product Every Year At least one new product every year through the end of the decade, launched within Harrow’s existing cost structure and commercial footprint 2026 2027 2028 2029 2030 LAUNCHED / ACQUIRED COMMERCIAL LAUNCH PIPELINE PIPELINE PIPELINE + BD BYOOVIZ OPUVIZ YOCHIL H

  6. Slide 6: Financials & Outlook

    Financials & Outlook 3Q26 | Results and Outlook Key Financial Metrics and Revenue Conversion 6 Corporate Presentation | November 2026

  7. Slide 7: Key Financial Metrics

    Key Financial Metrics FIVE-YEAR TRACK RECORD Q3 2026 KEY METRICS CONSOLIDATED REVENUE REVENUE BRANDED REVENUE ADJ. EBITDA $ in millions 41% 5-Yr CAGR (2020–2025) $99.3M $83.5M $21.2M +41% QoQ · +39% YoY +62% YoY · 84% of total vs. $(1.2)M in Q2 2026 $400M $357.5M (Midpoint) $272.3M PRODUCT REVENUE $

  8. Slide 8: Q4 Bridge: Path to FY2026 Guidance

    Q4 Bridge: Path to FY2026 Guidance Q4 implied by reaffirmed guidance, driven by new revenue sources, seasonal strength and product momentum Q3 TO IMPLIED Q4 REVENUE · $ IN MILLIONS WHAT Q4 REQUIRES +$36.5 – $51.5M $135.8 – $150.8M $135.8 – $150.8M Implied Q4 revenue at the low and high end of $99.3M

  9. Slide 9: Four Focused Selling Teams

    Four Focused Selling Teams Each team built around a common set of prescribers, care setting, and purchasing and reimbursement dynamics Ocular Surface Disease Retina Surgical Cornea specialists, dry eye practices, comprehensive Retina specialists & multi-specialty practices for in-office Cataract & r

  10. Slide 10: Ocular Surface Disease

    Ocular Surface Disease VEVYE | TYRVAYA | FRESHKOTE PF | FLAREX | VERKAZIA | ZERVIATE | NATACYN 10 Corporate Presentation | November 2026

  11. Slide 11: Ocular Surface Disease Portfolio

    Ocular Surface Disease Portfolio A broad ocular surface portfolio, sold by one commercial team calling on the same prescribers Q3 2026 Highlights VEVYE Cyclosporine ophthalmic Varenicline solution nasal Preservative-free lubricant Fluorometholone acetate Revenue of $39.7M, +75% YoY and solution 0.1%

  12. Slide 12: VEVYE: Best-in-Class for DED

    VEVYE: Best-in-Class for DED The first and only water-free cyclosporine for the signs and symptoms of dry eye disease MARKET OP PORT UNIT Y DED Patient Funnel ~22x More cyclosporine delivered into the cornea vs. Restasis Preclinical ex-vivo corneal penetration study data 38M+ Americans with dry eye

  13. Slide 13: VEVYE Q3 2026 Key Metrics

    VEVYE Q3 2026 Key Metrics +35% +17% +83% Revenue Growth TRx Growth TRx Growth Q3 ’26 vs. Q2 ’26 Q3 ’26 vs. Q2 ’26 Q3 ’26 vs. Q3 ’25 Quarterly Revenue Q3 Highlights U.S. net revenue | Q3 ’25 → Q3 ’26 Record Revenue, Continued Prescription Growth $45M • Record $39.7M in quarterly revenue (+75% YoY), w

  14. Slide 14: TYRVAYA: Integrated and Off to a Strong Start

    TYRVAYA: Integrated and Off to a Strong Start The only FDA-approved nasal spray for dry eye disease, now part of our Ocular Surface team alongside VEVYE INITIAL TRACTION UNDER HARROW ZERO … Contraindications · Ocular AEs · Label Warnings ~40 Continuity Early demand Experienced commercial Reps are ca

  15. Slide 15: The VERKAZIA Opportunity

    The VERKAZIA® Opportunity VKC is a chronic allergic eye disease — driven by immune dysregulation, across a spectrum (from highly underdiagnosed mild cases to severe and sight-threatening cases), which primarily affects children, but can reach into adulthood THE DISEASE SPECTRUM WHY IT MATTER S — THE

  16. Slide 16: The NATACYN Opportunity

    The NATACYN® Opportunity Blepharitis is not a single infection — it is a microbiome imbalance (or dysbiosis) of the eyelid margin, driven by multiple etiologic pathogens THE ETIOLOGIC TRIAD WHY IT MATTER S — THE CLINICAL GAP FUNGUS ON ~50% ~79% Demodex Mite: 300 – 400 micrometers (µm) Fungus (Hyphae

  17. Slide 17: Retina

    Retina IHEEZO | BYOOVIZ | OPUVIZ IOPIDINE | TRIESENCE | VIGAMOX 17 Corporate Presentation | November 2026

  18. Slide 18: Retina Portfolio

    Retina Portfolio A broad and complementary retina portfolio, supported by one established commercial team Q3 2026 Highlights IHEEZO Chloroprocaine HCl ophthalmic gel 3% Ranibizumab-nuna; LUCENTIS® biosimilar Aflibercept-yszy; EYLEA® biosimilar, Revenue of $25.3M, +15% YoY and launching 2027 +62% QoQ

  19. Slide 19: IHEEZO Overview

    IHEEZO Overview Physician-administered ophthalmic gel for ocular surface anesthesia; FDA-approved September 2022 First-in-Class Large TAM Reimbursement IP Runway First approved use of ~14M+ annual U.S. Permanent J-code Two Orange Book chloroprocaine in the ocular procedures (J2403) in the in-office

  20. Slide 20: IHEEZO Total Addressable Market

    IHEEZO Total Addressable Market All eight procedure categories are IHEEZO-applicable | CPT codes shown with each procedure Estimated Annual U.S. Procedure Volume (millions) Intravitreal Injections 67028 10.0M Laser Procedures 65855 / 66761 / 67210 1.5M Gonioscopy (Procedural) 92020 1.0M Foreign Body

  21. Slide 21: IHEEZO Q3 2026 Key Metrics

    IHEEZO Q3 2026 Key Metrics 62,210 +21% +62% Q4 Customer Unit Demand* Unit Demand Growth Sequential Revenue Growth Historically Strongest Quarter Q3 ’26; 5% below record Q2 ’26 Q3 ’26 vs. Q3 ’25 Q3 ’26 vs. Q2 ’26 Seasonal demand +21% YoY Q3 Highlights Quarterly Customer Unit Demand* Q3 ’26 vs. Q3 ’25

  22. Slide 22: IHEEZO QUELL Phase 4 Topline Results

    IHEEZO QUELL Phase 4 Topline Results Primary endpoint inconclusive; all exploratory findings favored IHEEZO on post-procedure pain and tolerability measures Successful Anesthesia Procedural Pain Pain Through 24 Hours Adverse Events Primary endpoint; non-inferiority not Identical cumulative pain scor

  23. Slide 23: Surgical

    Surgical TRIESENCE | MAXIDEX | NEVANAC | ILEVRO TOBRADEX ST | MAXITROL | VIGAMOX Pipeline: G-MELT | YOCHIL | Next-Gen TRIESENCE (H-N08) 23 Corporate Presentation | November 2026

  24. Slide 24: Surgical Portfolio

    Surgical Portfolio One surgeon, one surgical episode — a comprehensive portfolio spanning postoperative care Q3 2026 Highlights TRIESENCE Triamcinolone acetonide Dexamethasone ophthalmic Nepafenac ophthalmic Nepafenac ophthalmic Record quarter: revenue exceeded injectable suspension suspension 0.1%

  25. Slide 25: TRIESENCE Overview

    TRIESENCE Overview Injectable suspension (triamcinolone acetonide 40 mg/mL) with separate reimbursement in every Commercial Expansion into traditional care setting Ocular Inflammation Regulatory Only FDA-approved preservative-free synthetic corticosteroid for injectable ophthalmic use 7M+ Annual pot

  26. Slide 26: TRIESENCE Q3 2026 Key Metrics

    TRIESENCE Q3 2026 Key Metrics $10.7M 20,022 +37% +110% Revenue Customer Unit Demand* Sequential Unit Growth Unit Demand Growth Record quarterly revenue Strongest quarter under Harrow Q3 ’26 vs. Q2 ’26 Q3 ’26 vs. Q3 ’25 Quarterly Unit Demand +110% YoY Q3 Highlights Unit demand per quarter | Q1 ’25 →

  27. Slide 27: G-MELT: IV & Opioid-Free Sedation

    G-MELT: IV & Opioid-Free Sedation Fixed-dose sublingual tablet combining 3 mg midazolam + If FDA-approved, G-MELT could be the only on-label 50 mg ketamine (non-opioid) product for sedation during cataract surgery WHAT MAKES G-MELT DIFFERENT PATH TO LAUNCH Zydis® sublingual technology Dissolves in s

  28. Slide 28: YOCHIL: Pediatric Oral Midazolam ODT

    YOCHIL: Pediatric Oral Midazolam ODT Oral dissolving tablet delivering midazolam for sedation, anxiolysis, and amnesia prior to diagnostic, therapeutic, or endoscopic procedures in pediatric patients WHAT MAKES YOCHIL DIFFERENT De-risked clinical pathway PATH TO LAUNCH Extensive clinical dataset gen

  29. Slide 29: Upcoming Catalysts: Key Milestones Through 2027

    Upcoming Catalysts: Key Milestones Through 2027 Regulatory, clinical, commercial and corporate events expected between now and the end of 2027 Q4 2026 Jan 2027 Early 2027 2027 G-MELT NDA submission VEVYE coverage win FY 2026 results Investor Day Filing for sublingual cataract-surgery Major national

  30. Slide 30: References

    References Sources and footnotes for figures cited throughout this presentation Data sources Non-GAAP financial measures Market, prescription, and procedure data are drawn from IQVIA Adjusted EBITDA is defined as net income (loss), excluding the effects (including Xponent), PhilRx, Vestrum Health, M

Harrow — Q3 2026 Earnings Presentation on 6ix